Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer

Cancer

Volumn 97, Issue 8, 2003, Pages 2027-2034

  Takeuchi, Yoshito ^a,b   Kurohane, Kohta ^a   Ichikawa, Kanae ^a   Yonezawa, Sei ^a   Nango, Mamoru ^c   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Antiangiogenic cancer therapy; Benzoporphyrin derivative monoacid ring A; Drug delivery system; Photodynamic therapy; Polycation liposome

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; LIPOSOME; PHOTOSENSITIZING AGENT; POLYCATION; POLYETHYLENEIMINE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; BLOOD VESSEL OCCLUSION; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DESTRUCTION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; IMMUNOFLUORESCENCE; LASER; LIFESPAN; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; SARCOMA; SARCOMA CELL;

AIR SACS; AMINES; ANIMALS; ANTIGENS, CD31; APOPTOSIS; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE; GREEN FLUORESCENT PROTEINS; IN SITU NICK-END LABELING; LIPOSOMES; LUMINESCENT PROTEINS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYAMINES; POLYETHYLENEIMINE; PORPHYRINS; SARCOMA, EXPERIMENTAL; SKIN NEOPLASMS;

EID: 0344407444     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11283     Document Type: Article

References (30)

1. Gomer CJ. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol. 1991;54:1093-1107.
2. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol. 1992;55:145-157.
3. Bonnett R. Photosensitisers of the porphyrin and phthalocyanine series for photodynamic therapy. Chem Soc Rev. 1995;24:19-33.
4. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905.
5. Candide C, Morliere P, Maziere JC, et al. In vitro interaction of the photoactive anticancer porphyrin derivative photofrin II with low density lipoprotein, and its delivery to cultured human fibroblasts. FEBS Lett. 1986;207:133-138.
6. Maziere JC, Santus R, Morliere P, et al. Cellular uptake and photosensitizing properties of anticancer porphyrins in cell membranes and low and high density lipoproteins. J Photochem Photobiol B: Biol. 1990;6:61-68.
7. de Smidt PC, Versluis AJ, van Berkel TJ. Properties of incorporation, redistribution, and integrity of porphyrin-low-density lipoprotein complexes. Biochemistry. 1993;32:2916-2922.
8. Nakajima S, Takemura T, Sakata I. Tumor-localizing activity of porphyrin and its affinity to LDL, transferrin. Cancer Lett. 1995;92:113-118.
9. Shibata Y, Matsumura A, Yoshida F, et al. Competitive uptake of porphyrin and LDL via the LDL receptor in glioma cell lines: flow cytometric analysis. Cancer Lett. 2001;166:79-87.
10. Mayhew E, Vaughan L, Panus A, et al. Lipid-associated methylpheophorbide-a (hexyl-ether) as a photodynamic agent in tumor-bearing mice. Photochem Photobiol. 1993; 58:845-851.
11. 131Ilabelled Zn(II)-phthalocyanine as a radiodiagnostic agent for tumours. Cancer Lett. 1996;109:57-61.
12. Oku N, Saito N, Namba Y, et al. Application of long-circulating liposomes to cancer photodynamic therapy. Biol Pharm Bull. 1997;20:670-673.
13. Ciulla TA, Danis RP, Criswell M, et al. Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. Expert Opin Investig Drugs. 1999;8:2173-2182.
14. Fingar VH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer. 1999;79:1702-1708.
15. Kurohane K, Tominaga A, Sato K, et al. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 2001;167:49-56.
16. Yang Z, Lu X, Frazier DL, et al. Tumor cell-enhanced sensitivity of vascular endothelial cells to photodynamic therapy. Lasers Surg Med. 1994;15:342-350.
17. Dolmans DE, Kadambi A, Hill JS, et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res. 2002;62:4289-4294.
18. Dolmans DE, Kadambi A, Hill JS, et al. Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res. 2002;62:2151-2156.
19. Yamazaki Y, Nango M, Matsuura M, et al. Polycation liposomes, a novel nonviral gene transfer system, constructed from cetylated polyethylenimine. Gene Ther. 2000;7:1148-1155.
20. Oku N, Yamazaki Y, Matsuura M, et al. A novel non-viral gene transfer system, polycation liposomes. Adv Drug Deliv Rev. 2001;52:209-218.
21. Oku N, Doi K, Namba Y, et al. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int J Cancer. 1994;58:415-419.
22. Yatsunami J, Aoki S, Fukuno Y, et al. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol. 2000;17:1151-1156.
23. Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000;89:488-499.
24. Soffer SZ, Kim E, Moore JT, et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J Pediatr Surg. 2001;36:1781-1784.
25. Engbrecht BW, Menon C, Kachur AV, et al. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res. 1999;59:4334-4342.
26. Blagosklonny MV. Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors. Oncogene. 2001;20:395-398.
27. Araya R, Uehara T, Nomura Y. Hypoxia induces apoptosis in human neuroblastoma SK-N-MC cells by caspase activation accompanying cytochrome c release from mitochondria. FEBS Lett. 1998;439:168-172.
28. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485-490.
29. Riva C, Chauvin C, Pison C, et al. Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res. 1998;18:4729-4736.
30. Asai T, Shimizu K, Kondo M, et al. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. 2002;520:167-170.